In CKD, dapagliflozin reduced a composite of eGFR decline, end-stage kidney disease, or CV or renal mortality.
Where this comes from
- Record sourced from PubMed, PMID 33524285.
- Also identified by DOI 10.7326/ACPJ202102160-020.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Heerspink HJ, Stefánsson BV, Correa-Rotter R, et al. <b>Dapagliflozin in patients with chronic kidney disease.</b> N Engl J Med. 2020;383:1436-46. 32970396.
Medical subject headings
- Kidney Failure, Chronic
- Renal Insufficiency, Chronic